Sees Q4 revenue of approximately $200M, an increase of approximately 35% year-over-year; Continued trend of sequential improvement in adjusted EBITDA in the fourth quarter of 2024 “We concluded 2024 with continued strength in our core businesses, as genomics revenue is expected to grow at ~30% in Q4 and our data and services revenue is expected to grow at ~45%, such that we expect to deliver ~99% of our revenue guidance for 2024 and ~100% of our adjusted EBITDA guidance,” said Eric Lefkofsky, Founder and CEO of Tempus. “Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI teams with Genialis to develop RNA-based biomarker algorithms
- Tempus AI up after FDA issues draft guidance on AI use in drug decision making
- tempus AI Inc Class A call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment bought 348K shares of Tempus AI today
- Cathie Wood’s ARK Investment bought 335.7K shares of Tempus AI today